Alpha Tau to Host Investor Call to Review New Data from the Alpha DaRT® Recurrent Glioblastoma REGAIN Trial
Key Highlights
- ➤Alpha Tau (DRTS) will host Nov. 16 call on new REGAIN interim results
- ➤REGAIN studies Alpha DaRT in recurrent glioblastoma patients across U.S. centers
- ➤REGAIN expects enrollment of up to 20 patients with recurrent glioblastoma
- ➤Trial’s primary objective is evaluating Alpha DaRT treatment feasibility and safety
- ➤Alpha DaRT lacks U.S. commercialization approval outside approved clinical trials
Expert Statements
Joshua Palmer, REGAIN principal investigator, The Ohio State University
“[No direct quotation provided in the article.]”
Uzi Sofer, CEO of Alpha Tau Medical Ltd.
“[No direct quotation provided in the article.]”
Robert Den, MD, Chief Medical Officer of Alpha Tau Medical Ltd.
“[No direct quotation provided in the article.]”
Raphi Levy, CFO of Alpha Tau Medical Ltd.
“[No direct quotation provided in the article.]”
JERUSALEM, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq/TASE: DRTS, DRTSW) (“Alpha Tau”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT(®), today announced that it will host a conference call and webcast on Monday, Nov. 16, 2026, at 8:30 a.m. ET to discuss new interim results from REGAIN (Recurrent Glioblastoma Alpha DaRT Intratumoral Therapy), its U.S. multicenter trial exploring the use of Alpha DaRT in patients with recurrent glioblastoma. The call will take place on the back of the presentation of the results at the 31(st) Annual Meeting of the Society for Neuro-Oncology (SNO), to be held Nov. 12-15, 2026, in Philadelphia.
The call will feature REGAIN principal investigator Dr. Joshua Palmer of The Ohio State University; Uzi Sofer, CEO of Alpha Tau; Robert Den, MD, Chief Medical Officer of Alpha Tau; and Raphi Levy, CFO of Alpha Tau.
Get started
Create a free account to read the full story.